Brenton Ahrens
General Partner @ Canaan Partners
Menlo Park, United States
Brenton Ahrens is a Series B investor at Canaan Partners in Menlo Park focused on Biotechnology and Health Care. Brenton K. Ahrens is based out of Menlo Park, California and is the General Partner of Canaan Partners. Brenton previously worked at Johnson & Johnson as a Engineer. Brenton K. Ahrens attended the University of Dayton.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries Brenton Ahrens invests in
Stages Brenton Ahrens invests in
Countries Brenton Ahrens invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 11 (29%)
- Health Care 9 (24%)
- Medical Device 8 (21%)
- Medical 6 (16%)
- Pharmaceutical 5 (13%)
Stage
- Series B 6 (16%)
- Series A 5 (13%)
- Series C 4 (11%)
- Series D 4 (11%)
- Funding Round 3 (8%)
Country
- United States 13 (34%)
- United Kingdom 4 (11%)
- Ireland 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ThirtyFiveBio is a biotechnology agency | Venture - Series Unknown / Apr 15, 2025 | ||
| Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells toalter their appearance to the immune system.This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases. | $50M / Series B / May 23, 2024 | ||
| Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. | $25M / Series B / Apr 18, 2024 | ||
| illumicell AI combines patented AI algorithms and proprietary microscopy technology to test 50x faster, 20x more effectively, empowering every healthcare provider at the point of care – not just fertility clinics – with accessible, scalable fertility diagnostics. | $300K / Pre-Seed / Oct 09, 2023 | ||
| Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $50M / Series G / Mar 27, 2023 | ||
| Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells toalter their appearance to the immune system.This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases. | $49.2M / Series B / Jan 26, 2023 | ||
| Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $70M / Series F / Oct 29, 2020 | ||
| Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells toalter their appearance to the immune system.This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases. | $3.3M / Series A / Jan 09, 2020 | ||
| Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. | $13.2M / Series A / Dec 18, 2019 | ||
| Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells toalter their appearance to the immune system.This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases. | $12.9M / Series A / Feb 11, 2019 | ||
| See all 38 investments → | |||
Co-Investors
About Canaan Partners
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health, and medtech.
Canaan Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Deepak Kamra
General Partner
|
|||
Peter Farina
Executive in Residence
|
|||
Bob Williams
VC In Residence
|
|||
Brendan Dickinson
General Partner
|
|||
|
Brenton Ahrens
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brenton Ahrens invest in?
Brenton Ahrens invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brenton Ahrens?
Public channels for Brenton Ahrens include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brenton Ahrens last invest?
The most recent investment recorded for Brenton Ahrens closed in Apr 2025. Shizune tracks 38 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
